Use of thromboprophylaxis in palliative care patients: A survey among experts in palliative care, oncology, intensive care, and anticoagulation

American Journal of Hospice and Palliative Medicine

Volumn 25, Issue 2, 2008, Pages 127-131

  Kierner, Katharina A ^a   Gartner, Verena ^a   Schwarz, Maria ^a   Watzke, Herbert H ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Clinical stage; Low molecular weight heparin; Palliative care; Prophylaxis; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; FIBRINOLYTIC AGENT;

ADULT; AGED; ARTICLE; AUSTRIA; BRONCHUS TUMOR; CLINICAL PRACTICE; FEMALE; HEALTH PERSONNEL ATTITUDE; HEART ATRIUM FIBRILLATION; HUMAN; INTENSIVE CARE; KARNOFSKY PERFORMANCE STATUS; MALE; METHODOLOGY; MIDDLE AGED; ONCOLOGY; PALLIATIVE THERAPY; PATIENT SELECTION; PRACTICE GUIDELINE; PROGNOSIS; QUALITY OF LIFE; QUESTIONNAIRE; TREATMENT WITHDRAWAL; VENOUS THROMBOEMBOLISM;

ADULT; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; ATTITUDE OF HEALTH PERSONNEL; AUSTRIA; BRONCHIAL NEOPLASMS; FEMALE; FIBRINOLYTIC AGENTS; GUIDELINE ADHERENCE; HUMANS; INTENSIVE CARE; KARNOFSKY PERFORMANCE STATUS; MALE; MEDICAL ONCOLOGY; MIDDLE AGED; PALLIATIVE CARE; PATIENT SELECTION; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; QUALITY OF LIFE; QUESTIONNAIRES; VENOUS THROMBOEMBOLISM; WITHHOLDING TREATMENT;

EID: 41849113106     PISSN: 10499091     EISSN: None     Source Type: Journal    
DOI: 10.1177/1049909107310142     Document Type: Article

References (18)

1. White RH The epidemiology of venous thromboembolism. Circulation. 2003 ; 107: 4-8.
2. Malone PC, Augutter PS The aetiology of deep venous thrombosis. Qual J Med. 2006 ; 99: 581-593.
3. Blom JW, Doggen CJM, Osanto S., Rosendaal FR Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005 ; 293: 715-722.
4. Chew HK, Wun T., Harvey D., Zhou H., White RH Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006 ; 166: 458-464.
5. Alikhan R., Cohen AT, Combe S., et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med. 2004 ; 164: 963-968.
6. Johnson MJ, Sproule MW, Paul J. The prevalence and associated variables of deep venous thrombosis in patients with advanced cancer. Clin Oncol. 1999 ; 11: 105-110.
7. Noble SI, Finlay IG Have palliative care teams' attitudes toward venous thromboembolism changed? A survey of thromboprophylaxis practice across British specialist palliative care units in the years 2000 and 2005. J Pain Symptom Manage. 2006 ; 32: 38-43.
8. Noble SI, Nelson A., Turner C., Finlay IG Acceptability of low molecular weight heparin thromboprophylaxis for inpatients receiving palliative care: qualitative study. BMJ. 2006 ; 332: 577-580.
9. Chambers JC Prophylactic heparin in palliative care: to a challenging idea. BMJ. 2006 ; 332: 729.
10. Kakkar AK, Levine MN, Kadziola Z., et al. Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol. 2004 ; 22: 1944-1948.
11. World Health Organization. Definition of palliative care. Available at: http://www.who.int/cancer/palliative/definition/en/. Accessed July 17, 2007.
12. Rosenwax LK, McNamara B., Blackmore AM, Holman CD Estimating the size of a potential palliative care population. Palliat Med. 2005 ; 19: 556-562.
13. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004 ; 126 (suppl 3). 338S - 400S.
14. Maltoni M., Caraceni A., Brunelli C., et al. Steering Committee of the European Association for Palliative Care. Prognostic factors in advanced cancer patients: evidence-based clinical recommendations-a study by the Steering Committee of the European Association for Palliative Care. J Clin Oncol. 2005 ; 23: 6240-6248.
15. Bozetti F. Guidelines on artificial nutrition versus hydration in terminal cancer patients. Nutrition. 1996 ; 12: 163-167.
16. Lee AYY. Low molecular weight heparin versus coumarin for prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003 ; 349: 146-153.
17. Hutten BA, Prins MH, Gent M., Ginsberg J., Tijssen JGP, Bller HR Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol. 2000 ; 17: 3078-3083.
18. Kearon C. Natural history of venous thromboembolism. Circulation. 2003 ; 107: 122-133.